CD22 and Miyoshi myopathy: There are numerous targets to be applied to TriKE construct to sensitize NK cell to cancer cells, such as CD22 on ALL, PD-L1 on bladder cancer, NSCLC and various carcinoma, signaling lymphocyte activation molecule family 7 (SLAMF7) on MM, vascular endothelial growth factor receptor-2 (VEGFR-2) on gastric cancer [40, 75], CD47 on non-Hodgkin lymphoma and several carcinomas [96].